{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(1)"],"submitter":["Wang G"],"pubmed_abstract":["The global prevalence and disease burden of alphaherpesviruses infections, including human-infecting viruses such as HSV-1, HSV-2, and VZV, as well as animal-infecting viruses like PRV, BHV, CHV, and FHV, highlight the unmet need for more effective and universal antiviral strategies. However, there has been no significant progress in developing broad-spectrum interventions against herpesvirus. Here we report the identification of a broadly neutralizing antibody against alphaherpesviruses, 16F9, which targets the glycoprotein B (gB) of alphaherpesviruses and offers cross-protection against multiple viruses such as HSV-1, HSV-2, and PRV in mice. 16F9 demonstrated robust therapeutic efficacy in various female mouse models of herpesvirus diseases including PRV-induced viral encephalitis, HSV-1"],"journal":["Nature communications"],"pagination":["11144"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12708680"],"repository":["biostudies-literature"],"pubmed_title":["A broadly neutralizing antibody confers cross-genus protection against alphaherpesviruses by inhibiting gB-mediated membrane fusion."],"pmcid":["PMC12708680"],"pubmed_authors":["Huang C","Liu L","Wu C","Wang G","Yu H","Jiang Y","Gui M","Xia N","Chen Y","Sun H","Chen T","Xi X","Tian K","Chen K","Yuan Q","Zheng Q","Zeng Y","Yang C","Xin J","Li Y","Yang Y","Huang Y","Li S","Liu C","Huo N","Lin L"],"additional_accession":[]},"is_claimable":false,"name":"A broadly neutralizing antibody confers cross-genus protection against alphaherpesviruses by inhibiting gB-mediated membrane fusion.","description":"The global prevalence and disease burden of alphaherpesviruses infections, including human-infecting viruses such as HSV-1, HSV-2, and VZV, as well as animal-infecting viruses like PRV, BHV, CHV, and FHV, highlight the unmet need for more effective and universal antiviral strategies. However, there has been no significant progress in developing broad-spectrum interventions against herpesvirus. Here we report the identification of a broadly neutralizing antibody against alphaherpesviruses, 16F9, which targets the glycoprotein B (gB) of alphaherpesviruses and offers cross-protection against multiple viruses such as HSV-1, HSV-2, and PRV in mice. 16F9 demonstrated robust therapeutic efficacy in various female mouse models of herpesvirus diseases including PRV-induced viral encephalitis, HSV-1","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-06T04:13:11.592Z","creation":"2026-05-25T03:12:03.917Z"},"accession":"S-EPMC12708680","cross_references":{"pubmed":["41402251"],"doi":["10.1038/s41467-025-66099-8"]}}